Sector Update: Healthcare

By
A A A

Healthcare shares were fairly flat in pre-market trade on Thursday.

In healthcare stocks news, Geron ( GERN ) has announced the U.S. Food and Drug Administration has

removed the partial clinical hold on the investigator-sponsored clinical trial of imetelstat in myelofibrosis (Myelofibrosis IST). The partial clinical hold was placed in March 2014 due to a safety signal of hepatotoxicity identified in clinical trials.

And, Amgen ( AMGN ) and AstraZeneca ( AZN ) late Wednesday reported positive results from a Phase 2 study evaluating brodalumab in 168 patients with psoriatic arthritis.

Brodalumab is the companies' investigational treatment that binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signaling by blocking the binding of several IL-17 ligands to the receptor. The IL-17 pathway plays a central role in inducing and promoting inflammatory disease processes.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


This article appears in: Investing , Commodities

Referenced Stocks: GERN , AMGN , AZN

MT Newswires

MT Newswires

More from MT Newswires:

Related Videos

Stocks

Referenced

Most Active by Volume

53,043,796
  • $15.505 ▼ 0.10%
44,331,460
  • $94.7055 ▲ 0.82%
40,857,912
  • $2.475 ▲ 11.99%
37,695,172
  • $69.29 ▼ 0.16%
37,081,290
  • $34.805 ▲ 2.19%
36,857,232
  • $7.30 ▲ 2.96%
36,411,997
  • $44.74 ▼ 0.21%
31,545,268
  • $3.81 ▲ 0.79%
As of 7/22/2014, 03:55 PM